

FORM PTO 1462 (modified) INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Atty. Docket No. X12383N	Serial No 09/928,198
	Applicants James A. Hoffmann, Jirong Lu	
	Filing Date August 10, 2001	Group 1647

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Sub-class	Filing Date If Appropriate
RM	AK	5,270,057	12/14/1993	Andreas L.J. De Meere, et al.			
	AL	5,384,132	01/24/1995	Andreas L.J. De Meere, et al.			
	AM	4,589,402	05/20/1986	Gary D. Hodgen, et al.			
	AN	4,746,508	05/24/1988	Martin C. Carey, et al.			
	AO	5,945,187	08/31/1999	Thomas Buch-Rasmussen, et al.			
	AP	5,681,822	10/28/1997	Michael Bornstein, et al.			
	AQ	5,661,125	8/26/97	Strickland			
RM	AR	6,238,890	8/29/01	Boime, et al			

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Sub-class	Translation	
							yes	no
RM	BB	EP 0 920 873	12/7/98	EPO				
	BC	EP 0 652 766	7/29/93	EPO				
	BD	GB 839 300	8/25/58	United Kingdom				
	BE	EP 0 448 146	09/25/1991	EPO				
	BF	EP 0 853 945	07/22/1998	EPO				
RM	BG	WO 93/11788	06/24/1993	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

RM	CX	John G. Pierce & Thomas F. Parsons, "Glycoprotein Hormones: Structure and Function" Ann. Rev. Biochem. 50:465-95 (1981).
	CY	Jacques U. Baenziger & Eric D. Green, "Pituitary Glycoprotein Hormone Oligosaccharides: Structure, Synthesis and Function of the Asparagine-Linked Oligosaccharides on Lutropin, Follitropin, and Thyrotropin" Biochimica et Biophysica Acta 947:287-306 (1988).
	CZ	Vincenta Garcia-Campayo, et al., "Design of Stable Biologically Active Recombinant Lutropin Analogs" Nature Biotechnology 15:663-67 (1997).
RM	CAA	Richard L. Remmele, Jr., et al., "Interleukin-1 Receptor (IL-1R) Liquid Formulation Development Using Differential Scanning Calorimetry" Pharmaceutical Research 15(2):200-08 (1998).

EXAMINER Regina M. Wertz	DATE CONSIDERED 4/9/03
-----------------------------	---------------------------

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

paper NO. 15

RECEIVED
FEB 25 2003
TECH CENTER 1600/2003

FORM PTC 1449 (modified)	Atty. Docket No. X12383N	Serial No 09/928,198
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Applicants James A. Hoffmann, Jirong Lu	
	Filing Date August 10, 2001	Group 1647

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	CAB	Jonas Fransson, et al., "Solvent Effects on the Solubility and Physicochemical Stability of Human Insulin-Like Growth Factor 1" Pharmaceutical Research 14(5):606-12 (1997).
	CAC	Xanthe M. Lam, et al., "The Effect of Benzyl Alcohol on Recombinant Human Interferon-?" Pharmaceutical Research 14(6):725-29 (1997).
	CAD	Leo E. Reichert, Jr. & Rosemary B. Ramsey, "Dissociation of Human Follicle-Stimulating Hormone" The Journal of Biological Chemistry 250(8):3034-40 (1975).
	CAE	Judith C. Heikoop, et al., "Structure-based Design and Protein Engineering of Intersubunit Disulfide Bonds in Gonadotropins" Nature Biotechnology 15:658-62 (1997).
	CAF	M.J. Rafferty, et al., "Safety and Tolerability of a Multidose Formulation of Epoetin Beta in Dialysis Patients" Clinical Nephrology. 54(3):240-45 (2000).
	CAG	L.A.M. Frenken, et al., "Analysis of the Efficacy of Measures to Reduce Pain After Subcutaneous Administration of Epoetin Alfa" Nephrology Dialysis Transplantation 9:1295-98 (1994).
	CAH	Jan Trøst Jørgenson, "Improvement of Patient Convenience in Treatment with Growth Hormone" Journal of Pediatric Endocrinology 7(2):175-80 (1994).
	CAI	Nina Vahl, et al., "Bioavailability of Recombinant Human Growth Hormone in Different Concentrations and Formulations" Pharmacology & Toxicology 79:144-49 (1996).
	CAJ	Syed M. Amir, et al., "Phenol, A Potent Stimulator of Adenylate Cyclase in Human Thyroid Membranes" Endocrine Research Communications, 8(2):83-95 (1981).
	CAK	Wendy L. St. Peter, et al., "Pain Comparison After Subcutaneous Administration of Single-Dose Formulation Versus Multidose Formulation of Epogen in Hemodialysis Patients" American Journal of Kidney Diseases, 32(3):470-74 (1998).
	CAL	A.P.L.® Injection 5 000 IU and Injection 10 000 IU, http://home.intekom.com/pharm/akromed/apl-inj.html , as of 12/10/2002.
	CAM	Profasi® (chorionic gonadotropin for injection, USP) for Intramuscular Injection, package insert revised 1993.
	CAN	Pregnyl® (chorionic gonadotropin for injection, USP), http://www.organoninc.com/pi/pregnyl_pi.html , as of 12/10/2002.
	CAO	A.P.L.® (chorionic gonadotropin for injection, USP), For Intramuscular Injection Only, Physicians' Desk Reference, 51st Edition, p. 2805 (1997).
	CAP	Pregnyl® (chorionic gonadotropin for injection, USP), Physicians' Desk Reference, 51st Edition, p. 1878 (1997).
	CAQ	Profasi® (chorionic gonadotropin for injection, USP) for Intramuscular Injection, Physicians' Desk Reference, 51st Edition, pp. 2620-21 (1997).
	CAR	Thomas W. Strickland, et al, "The Kinetic and Equilibrium Parameters of Subunit Association and Gonadotropin Dissociation" The Journal of Biological Chemistry, 257 (6): 2954-2960 (1982).
	CAS	Pergonal®, Physician's Desk Reference ("PDR"), 29th Ed., 1975, pages 1366 - 1367.
	CAT	Pergonal®, Physician's Desk Reference ("PDR"), 49th Ed., 1995, pages 2325 - 2327.
	CAU	Pergonal®, Physician's Desk Reference ("PDR"), 51st Ed., 1997, pages 2618 - 2620.

EXAMINER 	DATE CONSIDERED 4/7/03
--------------	---------------------------

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

PAPER NO: 15

RECEIVED
FEB 25 2003
TECH CENTER 1600/2900

FORM 1449 (modified)

Atty. Docket No.
X12383NSerial No
09/928,198INFORMATION DISCLOSURE CITATION
IN AN APPLICATIONApplicants
James A. Hoffmann, Jirong LuFiling Date
August 10, 2001Group
1647

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

CAV	Pergonal®, Physician's Desk Reference ("PDR"), 54th Ed., 2000, pages 2946 - 2947.
CAW	Humegon®, PDR, 54th Ed., 2000, pages 2095 - 2097.
CAX	Metrodin®, PDR, 51st Ed., 1997, pages 2616 - 2618.
CAY	Fertinex®, PDR, 55th Ed., 2001, pages 3020 - 3022.
CAZ	Gonal-F®, PDR, 54th Ed., 2000, pages 2943 - 2946.
CBA	Follistim®, PDR, 54th Ed., 2000, pages 2092 - 2095.
CBB	A.P.L.®, PDR, 12th Ed., 1957, page 625.
CBC	A.P.L.®, PDR, 19th Ed., 1965, page 527.
CBD	A.P.L.®, PDR, 34th Ed., 1980, page 592.
CBE	Pregnyl®, PDR, 39th Ed., 1985, page 1450.
CBF	Progon®, PDR, 19th Ed., 1965, page 646.
CBG	Glukor®, PDR, 19th Ed., 1965, page 844.
CBH	Stemutrolin®, PDR, 24th Ed., 1970, page 867.
CBI	Follutein®, PDR, 24th Ed. 1970, pages 1249 -1250.
CBJ	Glucagon, PDR, 19th Ed., 1965, page 703.
CBK	Regular Iletin®, PDR, 19th Ed., 1965, page 705.
CBL	Asellacrin®, PDR, 34th Ed., 1980, pages 1605 - 1606.
CBM	Asellacrin®, PDR, 39th Ed., 1985, pages 1940 - 1941.
CBN	Humatrope®, PDR, 44th Ed., 1990, pages 1216 - 1217.
CBO	Protropin®, PDR, 44th Ed., 1990, pages 1002 - 1003.
CBP	Saizen®, PDR, 52nd Ed., 1998, page 2776 - 2777
CBQ	Epogen®, PDR, 51st Ed., 1997, pages 489 - 494.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

paper 1015

